Patents Examined by Marcela M. Cordero Garcia
-
Patent number: 12264183Abstract: The present invention relates to bacteriocins for control of Salmonella enterica (salmocins). The bacteriocins are derived from Salmonella. The salmocins can be expressed in plants and can be used in a method of preventing or reducing infection or contamination of an object with Salmonella.Type: GrantFiled: September 21, 2021Date of Patent: April 1, 2025Assignee: Nomad Bioscience GmbHInventors: Simone Hahn, Tobias Schneider, Anett Stephan, Steve Schulz, Anatoli Giritch, Yuri Gleba, Heike Prochaska
-
Patent number: 12257287Abstract: Provided are a polypeptide derivative, modified derivative or salt thereof, and use of the polypeptide derivative, modified derivative or salt thereof, wherein the polypeptide derivative, modified derivative or salt thereof comprises a polypeptide having the sequence of following general formula I, general formula I: HX2QGTFTSDX10SX12YLX15X16X17X18AX20 EFX23X24WLX27X28X29X30X31, wherein the definitions of X2, X10, X12, X15, X16, X17, X18, X20, X23, X24, X27, X28, X29, X30 and X31 are consistent with the definitions in the claims and the description. The polypeptide derivative provided by the invention has a dual agonistic effect on GC/GLP-1 receptors, so that a synergistic effect on energy metabolism is generated, which can effectively reduce blood glucose while reducing body weight and improving the body fat level, and the efficacy is better than that of a single GLP-1 receptor agonist.Type: GrantFiled: November 12, 2019Date of Patent: March 25, 2025Assignee: Tianjin Institute of Pharmaceutical Research Co., Ltd.Inventors: Yingmei Han, Wei Liu, Bingni Liu, Weiling Kong, Naxia Zhao, Guangping Xia, Qian Shang, Xiaohua Kong, Jing Jin, Yuquan Li, Xuyuan Liu
-
Patent number: 12252553Abstract: Disclosed are various crystalline salt forms of D-Arg-Dmt-Lys-Phe-NH2.Type: GrantFiled: December 2, 2022Date of Patent: March 18, 2025Assignee: Stealth BioTherapeutics Inc.Inventors: Scott M. Duncan, Martin P. Redmon
-
Patent number: 12251417Abstract: Cultures of Delftia bacteria are disclosed. Antimicrobial agents derived therefrom are also disclosed.Type: GrantFiled: December 13, 2021Date of Patent: March 18, 2025Assignees: Ministry of Health, State of Israel, Sami Shamoon College of Engineering (R.A), Tel HaShomer Medical Research lnfrastructure and Services Ltd.Inventors: Israel Nissan, Noa Lea Tejman-Yarden, Chaim Rubinovitz, Yakov Davidov, Galia Rahav, Ari Robinson, Yoram Shotland
-
Patent number: 12233107Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.Type: GrantFiled: July 12, 2023Date of Patent: February 25, 2025Assignee: The General Hospital CorporationInventor: Steven K. Grinspoon
-
Patent number: 12227492Abstract: Novel compounds and methods of using the compounds and compositions to treat pancreatic cancer are presented. Novel compounds N-(5-fluoro-2-oxo-1-(tetrahydrofuran-2-yl)-1,2-dihydropyrimidin-4-yl)octanamide and N-(5-fluoro-2-oxo-1-(tetrahydrofuran-2-yl)-1,2-dihydropyrimidin-4-yl)dodecanamide are provided. The compounds have been shown to induce cytotoxicity in pancreatic cancer cells and can serve as a novel oral treatment for pancreatic cancer.Type: GrantFiled: May 16, 2022Date of Patent: February 18, 2025Assignee: Florida A&M UniversityInventors: Edward Agyare, Xue You Zhu, Andriana Inkoom, Nkafu Bechem Ndemazie
-
Patent number: 12186408Abstract: The present invention provides fusion polypeptides for inhibiting angiogenesis, fusion protein nanocages having peptides for inhibiting angiogenesis, and diagnostic and therapeutic (theranostic) uses thereof.Type: GrantFiled: April 17, 2020Date of Patent: January 7, 2025Assignee: Industry-University Cooperation Foundation Hanyang University Erica CampusInventors: Dong Woo Lim, Min Jung Kang
-
Patent number: 12187767Abstract: The present application relates to methods and compositions and methods for treating viral infections, especially those caused by SARS-CoV-2. In one aspect, a method of treatment comprises administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a multipartite SARS-CoV-2-inhibiting peptide comprising a secretion modulating region (VI-SMR) peptide from HIV-1 Nef in combination with a cell-penetrating peptide (CPP) domain, a Clusterin (Clu)-binding peptide (Clu-BP) domain, a mitochondrial targeting (Mito-T) peptide domain, an anti-fusogenic (AF) peptide domain, a viral attachment inhibitor (VAI) domain or combination thereof, optionally where the SARS-CoV-2-inhibiting peptide is pegylated and/or modified with one or more hydrophobic domains.Type: GrantFiled: June 9, 2022Date of Patent: January 7, 2025Assignee: MOREHOUSE SCHOOL OF MEDICINEInventors: Vincent C. Bond, Ming Bo Huang, James W. Lillard, Jr.
-
Patent number: 12144844Abstract: This disclosure relates to treating internal disc disruption or a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-?1) or transforming growth factor beta 2 (TGF-?2), fibroblast growth factor (FGF), and a pharmaceutically acceptable excipient or a secondary agent.Type: GrantFiled: March 29, 2022Date of Patent: November 19, 2024Inventor: Bjorn Eek
-
Patent number: 12137682Abstract: The present invention provides peptoid polymers capable of reducing or inhibiting the formation of ice crystals at sub 0° C. temperatures. Also provided are peptoid-peptide hybrids comprising the peptoid polymers provided herein. The peptoid polymers and peptoid-peptide hybrids provided herein are useful for making cryoprotectant solutions. The peptoid polymers, peptoid-peptide hybrids, and cryoprotectant solutions provided herein are useful for making antifreeze solutions, frozen food products, and cosmetic care products. Also provided herein are methods for preserving a tissue, an organ, a cell, or a biological macromolecule using the compositions described herein.Type: GrantFiled: October 26, 2022Date of Patent: November 12, 2024Assignee: X-Therma, Inc.Inventor: Xiaoxi Wei
-
Patent number: 12133883Abstract: The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulation comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.Type: GrantFiled: August 28, 2020Date of Patent: November 5, 2024Assignee: Ascendis Pharma Endocrinology Division A/SInventors: Thomas Kurpiers, Harald Rau, Evelyn Exner, Steen Jensen, Grethe Nørskov Rasmussen, Torben Lessmann, Thomas Wegge, Alina Hermann, Nina Schubert, Anna Splanemann, Joachim Zettler
-
Patent number: 12128085Abstract: In an aspect, a method of manufacture of a pharmaceutically acceptable solid composition containing daptomycin includes drying an aqueous solution containing (i) water, (ii) the daptomycin, (iii) sorbitol in an amount of about 1.2 wt. % to about 9.0 wt. % of total volume of the aqueous composition and (iv) mannitol in an amount of about 0.6 wt. % to about 9.5 wt. % of total volume of the aqueous composition to form the solid composition. The drying can include an sublimation drying of about ?25° C. to about 50° C. for a time period of about 15 hours to about 120 hours, most preferably about 15° C. for about 20 hours, optionally preceded and/or followed by one or more additional drying steps. Other aspects are the solid composition containing the daptomycin and also methods of treating a bacterial infection including administering a pharmaceutically acceptable product made by reconstituting the solid composition.Type: GrantFiled: September 28, 2021Date of Patent: October 29, 2024Assignees: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SAInventors: Lindsay Wegiel, Reagan Miller
-
Patent number: 12127562Abstract: The present invention includes methods and compositions that produce greater pesticidal activity in FR901228 conjugates. FR901228 can be conjugated with one or more thiol containing molecules and produce a new conjugate that exhibits increase pesticidal activity than FR901228 alone.Type: GrantFiled: November 23, 2021Date of Patent: October 29, 2024Assignee: Pro Farm Group, Inc.Inventors: Brittany Pierce, Scott Burman
-
Patent number: 12116387Abstract: Provided herein are synthetic peptides with enhanced antimicrobial and antibiofilm characteristics, and are biocompatible with mammalian cellular systems. The disclosed synthetic antimicrobial moieties include a mastoparan peptide having SEQ ID NO:1 and a pentapeptide motif formed from phenylalanine, leucine, proline, and two isoleucine residues, wherein the pentapeptide motif is conjugated the N-terminus of the mastoparan peptide. Also provided are compositions comprising the synthetic peptides, as well as methods of treating a microbial infection or removing a biofilm using the peptides.Type: GrantFiled: September 14, 2022Date of Patent: October 15, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Marcelo Der Torossian Torres, Cesar de la Fuente-Nunez, Gislaine G. O. Silva, Octavio L Franco
-
Patent number: 12110338Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: August 17, 2021Date of Patent: October 8, 2024Assignee: Genzyme CorporationInventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Patent number: 12091693Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.Type: GrantFiled: October 8, 2021Date of Patent: September 17, 2024Assignee: PURDUE RESEARCH FOUNDATIONInventors: Philip Stewart Low, Venkatesh Chelvam, Youngsoon Kim, Sumith A Kularatne
-
Patent number: 12084480Abstract: Described herein are unstructured polypeptides lacking any discernible repeat motif. Also described herein are fusion proteins including at least one of the unstructured polypeptides and at least one binding polypeptide. Further described are methods for treating a disease in a subject in need thereof. The methods may include administering to the subject an effective amount of the fusion protein.Type: GrantFiled: September 16, 2021Date of Patent: September 10, 2024Assignee: Duke UniversityInventors: Ashutosh Chilkoti, Nicholas Tang, Garrett Kelly
-
Patent number: 12077612Abstract: The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.Type: GrantFiled: October 26, 2020Date of Patent: September 3, 2024Assignee: RHYTHM PHARMACEUTICALS, INC.Inventors: Shubh Sharma, Leonardus H. T. Van Der Ploeg, Bart Henderson
-
Patent number: 12064467Abstract: The present disclosure generally relates to systems and methods for delivering humanin and/or other peptides to a subject. In some cases, these may be used for treating or preventing aging skin, or for other diseases. Non-limiting examples of other peptides include mitochondrial-derived peptides such as HNG or MOTS-c. In addition, certain embodiments are generally directed to treatments that can be delivered using topical compositions applied to the skin. For example, in some cases, the composition includes lecithin and/or other components that may facilitate delivery through the skin. Further, certain embodiments may include active ingredients such as tributyrin or 2,6-dimethyl-L-tyrosine, which may interact with humanin or other peptides. Compositions such as these may be used in certain embodiments, for example, to reduce inflammation within the skin, or as an anti-aging treatment, etc.Type: GrantFiled: October 28, 2022Date of Patent: August 20, 2024Assignee: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Patent number: 12037368Abstract: Computational systems and methods are described for identifying new type-II bacteriocins using a systemic consensus formula and other related criteria. Newly identified type-II bacteriocin peptides are tested experimentally and show potent microbiocidal activities.Type: GrantFiled: September 7, 2021Date of Patent: July 16, 2024Assignee: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterInventors: Nannette Y. Yount, Michael R. Yeaman